Article

Vitamin B6 treatment in acute neuroleptic-induced akathisia: a randomized, double-blind, placebo-controlled study.

Mental Health Center, Faculty of Health Sciences Ben-Gurion University of the Negev, Be'er-Sheva, Israel.
The Journal of Clinical Psychiatry (Impact Factor: 5.14). 12/2004; 65(11):1550-4. DOI: 10.4088/JCP.v65n1118
Source: PubMed

ABSTRACT Treatment strategies for acute neuroleptic-induced akathisia (NIA) contain anticholinergic (antimuscarinic) agents, dopamine agonists, gamma-aminobutyric acid (GABA)-ergic agents, beta-blockers, benzodiazepines, and serotonin antagonists. Nevertheless, many patients who suffer from acute akathisia fail to respond to treatment. In earlier studies, vitamin B6 was found to be effective in the treatment of neuroleptic-induced movement disorders. The purpose of this study was to evaluate the efficacy of vitamin B6 in the treatment of acute NIA. This is the first report of B6 as a treatment for NIA.
This study was conducted in 2 mental health centers from February 2003 to November 2003. Twenty schizophrenia and schizoaffective inpatients with a DSM-IV diagnosis of NIA were randomly divided to receive vitamin B6 600 mg/day b.i.d. (N = 10) or placebo (N = 10) twice a day for 5 days in a double-blind design. The Barnes Akathisia Scale (BAS), the Brief Psychiatric Rating Scale (BPRS), and the Clinical Global Impressions scale (CGI) were used to assess the severity of NIA and psychotic symptoms. The BAS assessment was made at baseline and every day during the study. The BPRS and CGI were completed at baseline and at the end of the study.
The vitamin B6-treated patients in comparison with the placebo group showed a significant improvement on the subjective-awareness of restlessness (p = .0004), subjective-distress (p = .01), and global (p = .004) subscales of the BAS. The objective subscale did not demonstrate significant positive results (p = .079), but there was a trend of symptom amelioration in the vitamin B6 group. A reduction of at least 2 points on the BAS global subscale was noted in 8 patients in the vitamin B6 group (80%), and in only 3 patients in the placebo group (30%) (p = .037).
Our preliminary results indicate that high doses of vitamin B6 may be useful additions to the available treatments for NIA, perhaps due to its combined effects on various neurotransmitter systems.

2 Bookmarks
 · 
425 Views
  • Source
    Article: vitamin b6
    [Show abstract] [Hide abstract]
    ABSTRACT: Objective: The authors’ goal was to conduct a double-blind trial of vitamin B6 in the treatment of tardive dyskinesia in patients with schizophrenia. Method: Fifteen inpatients with schizophrenia who met research diagnostic criteria for tardive dyskinesia were randomly assigned to treatment with either vitamin B6 or placebo for 4 weeks in a double-blind crossover paradigm. The Extrapyramidal Symptom Rating Scale was used to assess patients weekly. Results: Mean scores on the parkinsonism and dyskinetic movement subscales of the Extrapyramidal Symptom Rating Scale were significantly better in the third week of treatment with vitamin B6 than during the placebo period. Conclusions: Vitamin B6 appears to be effective in reducing symptoms of tardive dyskinesia.
    American Journal of Psychiatry 01/2001; 158:1511-1514. · 14.72 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: The syndrome of schizophrenia is marked by changes in the afflicted person's functioning, perception, thinking, and behaviour. The mainstay of treatment involves antipsychotic medications (either the older generation, and /or more commonly, the newer atypical antipsychotic medications), often combined with other psychiatric medications (e.g., anxiolytics, hypnotics, mood stabilizers, and/ or antidepressants), as well as some psychoeducation. The "typical" schizophrenic patient seeking out the author's care has either been ill for a brief time (perhaps a year or less) or many years, has relapsed once or several times following the abrupt discontinuation of medication, has developed physical problems from medication (e.g., weight gain and tardive dyskinesia), and has accumulated a host of disabling behavioural and emotional coping strategies. Specific orthomolecular substances can reduce symptoms of psychosis, attenuate weight gain, and help to reduce symptoms of tardive dyskinesia and even neuroleptic-induced akathisia. Unfortunately, the long-term use of antipsychotic and other psychiatric drugs given to assuage symptoms of schizophrenia often cause devastating impacts on the bodies and brains of the individuals that take them. This makes it difficult, if not impossible for the orthomolecular approach to help patients fully recover.
    Journal of Orthomolecular Medicine 01/2014; 29(4):141-153.
  • Source
    Journal of Orthomolecular Medicine 01/2013; 28(1):17-32.

Full-text (3 Sources)

Download
119 Downloads
Available from
May 20, 2014